. 2017 Oct 4;16:124. doi: 10.1186/s12933-017-0602-y

Table 2.

Effects of pemafibrate on atherogenic apolipoproteinB-containing lipoproteins in a phase II dose-ranging study

Adapted from Ishibashi et al. [56].

Parameter	Placebo, (n = 35)	Pemafibrate (K-877) mg/day				Fenofibrate mg/day 100 (n = 36)
Parameter	Placebo, (n = 35)	0.05 (n = 34)	0.1 (n = 37)	0.2 (n = 36)	0.4 (n = 36)	Fenofibrate mg/day 100 (n = 36)
Total C	0.1 ± 9.8	−2.7 ± 11.4	−6.5 ± 11.9**^†	−7.0 ± 11.3***^†	−5.3 ± 12.9*	−6.0 ± 11.8**^†
Non-HDL-C	0.7 ± 12.8	−5.8 ± 12.4*	−11.8 ± 14.0***^†††	−12.2 ± 13.8***^†††	−10.5 ± 14.2***^†††	−10.1 ± 14.2***^††
VLDL-C^a	13.3 ± 38.9	−24.3 ± 24.0***^†††	−37.3 ± 26.7***^†††	−43.8 ± 24.0***^†††	−48.4 ± 27.5***^†††	−25.8 ± 29.7***^†††
LDL-C^a	−6.3 ± 16.2*	8.9 ± 21.3*^†	8.3 ± 29.4^†	5.0 ± 28.0	7.4 ± 26.5^†	5.3 ± 23.4^†
Remnant C	38.7 ± 75.7**	−32.3 ± 33.8***^†††	−42.8 ± 29.4***^†††	−48.3 ± 28.1***^†††	−50.1 ± 31.8***^†††	−31.8 ± 35.0***^†††
ApoB	−2.0 ± 9.9	−1.4 ± 13.6	−8.9 ± 13.6***^†	−7.8 ± 15.0**	−8.1 ± 11.6***	−5.7 ± 14.4*
ApoB48	54.6 ± 171.1	−28.4 ± 43.1***^†††	−43.1 ± 47.1***^†††	−55.9 ± 25.6***^†††	−51.2 ± 29.3***^†††	−37.9 ± 42.9***^†††
ApoCIII	7.9 ± 27.4	−22.2 ± 14.4***^†††	−29.0 ± 18.9***^†††	−34.6 ± 17.7***^†††	−33.4 ± 19.2***^†††	−27.2 ± 18.9***^†††

Data are given as mean ± standard deviation (SD) for the percent change from baseline to week 12

Apo apolipoprotein, C cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein, VLDL very low-density lipoprotein

Significantly different from baseline (week 0) * p < 0.05, ** p < 0.01, *** p < 0.001

Significantly different from placebo ^† p < 0.05, ^†† p < 0.01, ^††† p < 0.001

Figures in italics: significantly different from fenofibrate p < 0.01

^aMeasured by ultracentrifugation